Voglidyn M 0.2

Voglibose 0.2 mg + Metformin (strength unknown)

Treatment of type 2 diabetes mellitus to improve post-meal and overall blood glucose control, usually when diet/exercise alone or single-drug therapy is insufficient.

Voglibose is an alpha-glucosidase inhibitor that delays breakdown and absorption of carbohydrates in the intestine, reducing post-meal glucose spikes. Metformin decreases hepatic glucose production and improves insulin sensitivity, helping lower fasting and overall blood glucose.

Oral tablet. Take exactly as prescribed. Voglibose-containing tablets are usually taken just before meals/with the first bite; metformin is generally taken with food to reduce stomach upset. Swallow whole with water; do not skip meals.

Flatulence, abdominal pain, diarrhea, nausea, vomiting, loss of appetite, metallic taste, headache, dizziness

For type 2 diabetes only. Risk of low blood sugar increases when used with insulin or sulfonylureas—recognize symptoms and treat promptly. Metformin may rarely cause lactic acidosis; seek urgent care for rapid breathing, severe weakness, abdominal pain, or unusual sleepiness. Use caution/avoid in severe kidney impairment, severe liver disease, severe infection, dehydration, or hypoxia; kidney function monitoring is advised. Temporarily stop metformin around iodinated contrast procedures or major surgery as advised by doctor. Gastrointestinal side effects are common initially.

Insulin, sulfonylureas (e.g., glimepiride), alcohol, iodinated contrast media, cimetidine, carbonic anhydrase inhibitors (e.g., topiramate), diuretics, corticosteroids, thyroid hormones, beta-agonists

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Voglibose + Metformin (same strength) combinations from other brands (exact brand equivalents vary by strength)